Biotech · Private company
Immunocore Ltd
Track this companyFree. Adds Immunocore Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials156 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline24
- BrenetafuspPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Investigators ChoicePhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Nivolumab + RelatlimabPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- TebentafuspPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Tebentafusp with PembrolizumabPhase 3 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- BrenetafuspPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Brenetafusp and bevacizumabPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Brenetafusp and chemotherapyPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Brenetafusp and monoclonal antibodies and chemotherapyPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Brenetafusp and pembrolizumabPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Brenetafusp and tebentafuspPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- DacarbazinePhase 2 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IMC-C103CPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IMCgp100Phase 2 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IMCgp100Phase 2 · Malignant MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IMCnyesoPhase 2 · Select Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Tebentafusp (IMCgp100)Phase 2 · Malignant MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- HBV HCC Module MADPhase 1 · Hepatitis B, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- IMC-I109V Multiple Ascending DosesPhase 1 · Hepatitis B, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- IMC-I109V Single Ascending DosePhase 1 · Hepatitis B, ChronicClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With TebentafuspPHASE2 · WITHDRAWN · started Nov 1, 2026ClinicalTrials.gov NCT07803562 · fetched Nov 12, 2026
- Neoadjuvant Tebentafusp for Uveal MelanomaPHASE2 · RECRUITING · started Sep 5, 2025ClinicalTrials.gov NCT06414590 · fetched Nov 12, 2026
- Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal MelanomaPHASE2 · RECRUITING · started Aug 18, 2025ClinicalTrials.gov NCT06070012 · fetched Nov 12, 2026
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal MelanomaPHASE2 · RECRUITING · started Feb 14, 2025ClinicalTrials.gov NCT06627244 · fetched Nov 12, 2026
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)PHASE3 · RECRUITING · started Jun 5, 2024ClinicalTrials.gov NCT06112314 · fetched Nov 12, 2026
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)PHASE3 · RECRUITING · started Dec 19, 2022ClinicalTrials.gov NCT05549297 · fetched Nov 12, 2026
- Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV InfectionPHASE1 · WITHDRAWN · started Aug 12, 2020ClinicalTrials.gov NCT05867056 · fetched Nov 12, 2026
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 25, 2020ClinicalTrials.gov NCT04262466 · fetched Nov 12, 2026
- Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabPHASE1_PHASE2 · WITHDRAWN · started May 17, 2019ClinicalTrials.gov NCT03973333 · fetched Nov 12, 2026
- Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive CancersPHASE1_PHASE2 · TERMINATED · started Jun 15, 2018ClinicalTrials.gov NCT03515551 · fetched Nov 12, 2026
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaPHASE2 · COMPLETED · started Oct 16, 2017ClinicalTrials.gov NCT03070392 · fetched Nov 12, 2026
- IMCgp100-401 Rollover StudyPHASE2 · TERMINATED · started Jan 11, 2017ClinicalTrials.gov NCT02889861 · fetched Nov 12, 2026
- A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal MelanomaPHASE1_PHASE2 · COMPLETED · started Feb 29, 2016ClinicalTrials.gov NCT02570308 · fetched Nov 12, 2026
- Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaPHASE1_PHASE2 · WITHDRAWN · started Nov 1, 2015ClinicalTrials.gov NCT02535078 · fetched Nov 12, 2026
- Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant MelanomaPHASE1 · COMPLETED · started Sep 28, 2010ClinicalTrials.gov NCT01211262 · fetched Nov 12, 2026